Join us on our journey to
end blood cancer.
We are the only foundation in the world that supports patients with RUNX1-FPD.
Take part in shaping a future where blood cancer doesn’t exist.
What is RUNX1 Familial Platelet Disorder (RUNX1-FPD)?
RUNX1-FPD (also known as RUNX1-FPDMM or FPD-AML) is a rare inherited disease caused by a mutation in the RUNX1 gene, resulting in lower blood platelet counts, platelet dysfunction, and an increased risk of early-onset blood cancers.
Individuals with this disease primarily develop acute myeloid leukemia (AML), the second deadliest blood cancer.
RUNX1-FPD patients often face a range of health issues including asthma, allergies, autoimmune disorders and gastrointestinal problems. Discovered in 1999, this disease varies greatly between families, even within families, with some having a significantly higher incidence of blood cancer development.
There is a 50% chance for each child to have the RUNX1 mutation, no matter if they are male or female.
